Petter Bjornstad
Concepts (398)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetic Nephropathies | 78 | 2025 | 294 | 24.260 |
Why?
| | Diabetes Mellitus, Type 2 | 69 | 2025 | 2531 | 10.640 |
Why?
| | Diabetes Mellitus, Type 1 | 79 | 2025 | 3715 | 9.980 |
Why?
| | Glomerular Filtration Rate | 64 | 2025 | 746 | 8.410 |
Why?
| | Kidney | 51 | 2025 | 1468 | 6.060 |
Why?
| | Uric Acid | 23 | 2022 | 163 | 4.640 |
Why?
| | Albuminuria | 23 | 2024 | 185 | 4.190 |
Why?
| | Insulin Resistance | 20 | 2024 | 1208 | 4.110 |
Why?
| | Renal Insufficiency, Chronic | 21 | 2025 | 617 | 3.410 |
Why?
| | Hemodynamics | 23 | 2025 | 1113 | 2.830 |
Why?
| | Pediatric Obesity | 8 | 2023 | 601 | 2.780 |
Why?
| | Metformin | 12 | 2025 | 331 | 2.760 |
Why?
| | Renal Insufficiency | 6 | 2023 | 162 | 2.700 |
Why?
| | Coronary Artery Disease | 11 | 2022 | 698 | 2.520 |
Why?
| | Diabetic Angiopathies | 9 | 2019 | 259 | 2.420 |
Why?
| | Biomarkers | 36 | 2025 | 4149 | 2.410 |
Why?
| | Glycopeptides | 10 | 2021 | 43 | 2.250 |
Why?
| | Hypoglycemic Agents | 22 | 2025 | 1291 | 2.180 |
Why?
| | Bariatric Surgery | 5 | 2020 | 217 | 2.170 |
Why?
| | Vascular Calcification | 6 | 2022 | 108 | 2.130 |
Why?
| | Obesity, Morbid | 5 | 2020 | 264 | 2.100 |
Why?
| | Adolescent | 66 | 2025 | 21513 | 2.010 |
Why?
| | Renin-Angiotensin System | 10 | 2021 | 85 | 1.920 |
Why?
| | Sodium-Glucose Transporter 2 | 12 | 2024 | 24 | 1.890 |
Why?
| | Humans | 172 | 2025 | 137585 | 1.730 |
Why?
| | Glucosides | 11 | 2025 | 44 | 1.620 |
Why?
| | Sex Characteristics | 6 | 2025 | 762 | 1.610 |
Why?
| | Creatinine | 18 | 2025 | 499 | 1.610 |
Why?
| | Cardiovascular Diseases | 15 | 2024 | 2111 | 1.590 |
Why?
| | Young Adult | 47 | 2025 | 13209 | 1.580 |
Why?
| | Benzhydryl Compounds | 11 | 2025 | 73 | 1.580 |
Why?
| | Diabetic Ketoacidosis | 4 | 2025 | 201 | 1.460 |
Why?
| | Male | 104 | 2025 | 67762 | 1.450 |
Why?
| | Disease Progression | 19 | 2024 | 2757 | 1.400 |
Why?
| | Female | 99 | 2025 | 73304 | 1.360 |
Why?
| | Calcinosis | 4 | 2015 | 235 | 1.300 |
Why?
| | Obesity | 12 | 2025 | 2992 | 1.230 |
Why?
| | Adult | 59 | 2025 | 37929 | 1.190 |
Why?
| | Diabetic Cardiomyopathies | 4 | 2020 | 36 | 1.160 |
Why?
| | Kidney Diseases | 3 | 2023 | 408 | 1.160 |
Why?
| | Risk Factors | 36 | 2024 | 10388 | 1.080 |
Why?
| | Hyperglycemia | 6 | 2025 | 347 | 1.070 |
Why?
| | Child | 35 | 2025 | 21935 | 1.060 |
Why?
| | Glucagon-Like Peptides | 2 | 2025 | 58 | 1.050 |
Why?
| | Adiposity | 5 | 2024 | 518 | 1.020 |
Why?
| | Follow-Up Studies | 18 | 2025 | 5131 | 0.980 |
Why?
| | Arterioles | 3 | 2024 | 52 | 0.970 |
Why?
| | Acute Kidney Injury | 6 | 2025 | 815 | 0.970 |
Why?
| | Hypertension | 9 | 2021 | 1295 | 0.970 |
Why?
| | Exercise Tolerance | 3 | 2017 | 279 | 0.950 |
Why?
| | Fructose | 4 | 2021 | 112 | 0.940 |
Why?
| | Atherosclerosis | 4 | 2018 | 415 | 0.940 |
Why?
| | Apolipoproteins B | 2 | 2015 | 43 | 0.930 |
Why?
| | Vascular Stiffness | 7 | 2022 | 494 | 0.920 |
Why?
| | Uromodulin | 3 | 2019 | 21 | 0.910 |
Why?
| | Body Composition | 3 | 2025 | 684 | 0.910 |
Why?
| | Proteinuria | 2 | 2024 | 97 | 0.910 |
Why?
| | Hyperuricemia | 6 | 2021 | 44 | 0.900 |
Why?
| | Cross-Sectional Studies | 19 | 2025 | 5472 | 0.890 |
Why?
| | Vasopressins | 3 | 2023 | 64 | 0.890 |
Why?
| | Middle Aged | 52 | 2025 | 33479 | 0.880 |
Why?
| | Immunoglobulin Fc Fragments | 1 | 2024 | 41 | 0.880 |
Why?
| | Case-Control Studies | 14 | 2025 | 3556 | 0.870 |
Why?
| | Adiponectin | 2 | 2016 | 244 | 0.870 |
Why?
| | Blood Glucose | 13 | 2025 | 2186 | 0.840 |
Why?
| | Prognosis | 12 | 2025 | 4030 | 0.830 |
Why?
| | Hyperoxia | 1 | 2024 | 90 | 0.810 |
Why?
| | Iothalamic Acid | 1 | 2022 | 5 | 0.800 |
Why?
| | Dyslipidemias | 5 | 2021 | 176 | 0.800 |
Why?
| | Kidney Tubules | 2 | 2021 | 117 | 0.800 |
Why?
| | Diabetic Retinopathy | 4 | 2021 | 189 | 0.790 |
Why?
| | Blood Pressure | 10 | 2025 | 1786 | 0.770 |
Why?
| | Cystatin C | 8 | 2023 | 65 | 0.760 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2024 | 209 | 0.760 |
Why?
| | Kidney Glomerulus | 5 | 2023 | 119 | 0.730 |
Why?
| | Recombinant Fusion Proteins | 1 | 2024 | 665 | 0.730 |
Why?
| | Bone Density | 1 | 2025 | 489 | 0.700 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2024 | 262 | 0.660 |
Why?
| | Oxygen Consumption | 3 | 2017 | 696 | 0.650 |
Why?
| | Dried Blood Spot Testing | 2 | 2018 | 104 | 0.640 |
Why?
| | Iohexol | 2 | 2020 | 23 | 0.640 |
Why?
| | Triglycerides | 3 | 2022 | 524 | 0.640 |
Why?
| | Kidney Failure, Chronic | 4 | 2023 | 570 | 0.630 |
Why?
| | Oxygen | 2 | 2024 | 931 | 0.630 |
Why?
| | Vascular Resistance | 6 | 2020 | 375 | 0.620 |
Why?
| | Cyclic GMP | 1 | 2019 | 93 | 0.610 |
Why?
| | Longevity | 6 | 2022 | 165 | 0.610 |
Why?
| | Lipid Metabolism Disorders | 1 | 2018 | 3 | 0.610 |
Why?
| | Pilot Projects | 7 | 2024 | 1710 | 0.600 |
Why?
| | Coronary Vessels | 3 | 2017 | 248 | 0.600 |
Why?
| | Cohort Studies | 18 | 2025 | 5742 | 0.580 |
Why?
| | Weight Reduction Programs | 1 | 2019 | 117 | 0.580 |
Why?
| | Gastric Bypass | 1 | 2020 | 119 | 0.580 |
Why?
| | Leptin | 2 | 2017 | 236 | 0.580 |
Why?
| | Cardiotonic Agents | 1 | 2018 | 124 | 0.570 |
Why?
| | Overweight | 3 | 2025 | 558 | 0.570 |
Why?
| | Hemofiltration | 1 | 2018 | 30 | 0.570 |
Why?
| | Sodium Bicarbonate | 1 | 2018 | 45 | 0.560 |
Why?
| | Cholesterol, HDL | 2 | 2015 | 203 | 0.560 |
Why?
| | Glucose | 5 | 2023 | 1020 | 0.550 |
Why?
| | Ventricular Function, Left | 3 | 2020 | 534 | 0.540 |
Why?
| | Incidence | 9 | 2021 | 2804 | 0.540 |
Why?
| | Blood Vessels | 1 | 2018 | 187 | 0.540 |
Why?
| | Aorta | 2 | 2019 | 417 | 0.530 |
Why?
| | Up-Regulation | 2 | 2016 | 843 | 0.510 |
Why?
| | Nutrition Surveys | 1 | 2017 | 266 | 0.500 |
Why?
| | Cholesterol, LDL | 2 | 2014 | 365 | 0.490 |
Why?
| | Kidney Function Tests | 4 | 2022 | 160 | 0.470 |
Why?
| | Renal Circulation | 3 | 2021 | 58 | 0.470 |
Why?
| | Aged | 30 | 2025 | 23961 | 0.460 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2014 | 7 | 0.450 |
Why?
| | Pregnancy Outcome | 1 | 2017 | 416 | 0.450 |
Why?
| | Canada | 7 | 2022 | 418 | 0.450 |
Why?
| | Insulin | 7 | 2025 | 2409 | 0.440 |
Why?
| | Body Mass Index | 9 | 2025 | 2389 | 0.440 |
Why?
| | Sodium | 5 | 2025 | 217 | 0.430 |
Why?
| | Fasting | 2 | 2025 | 281 | 0.430 |
Why?
| | Echocardiography | 2 | 2018 | 642 | 0.430 |
Why?
| | Hypoxia | 2 | 2020 | 1112 | 0.430 |
Why?
| | Natriuresis | 3 | 2025 | 15 | 0.430 |
Why?
| | Dietary Supplements | 1 | 2018 | 561 | 0.420 |
Why?
| | Patient Care Planning | 1 | 2014 | 157 | 0.410 |
Why?
| | Goals | 1 | 2015 | 170 | 0.410 |
Why?
| | Drug Therapy, Combination | 5 | 2025 | 1066 | 0.410 |
Why?
| | Brain | 1 | 2025 | 2668 | 0.400 |
Why?
| | Vasoconstriction | 3 | 2020 | 202 | 0.400 |
Why?
| | Chitinase-3-Like Protein 1 | 2 | 2022 | 19 | 0.390 |
Why?
| | Heart Failure | 3 | 2021 | 2236 | 0.390 |
Why?
| | Histidine | 2 | 2022 | 64 | 0.380 |
Why?
| | Contrast Media | 1 | 2015 | 467 | 0.380 |
Why?
| | Lipids | 2 | 2022 | 672 | 0.370 |
Why?
| | Age of Onset | 2 | 2025 | 518 | 0.370 |
Why?
| | Glucose Clamp Technique | 5 | 2020 | 195 | 0.360 |
Why?
| | Albumins | 3 | 2022 | 114 | 0.350 |
Why?
| | Angiotensin II | 3 | 2020 | 99 | 0.350 |
Why?
| | Clinical Trials as Topic | 6 | 2022 | 1050 | 0.350 |
Why?
| | Guideline Adherence | 1 | 2015 | 556 | 0.330 |
Why?
| | Absorptiometry, Photon | 2 | 2025 | 259 | 0.330 |
Why?
| | Lipocalin-2 | 2 | 2022 | 79 | 0.330 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2014 | 445 | 0.320 |
Why?
| | Prospective Studies | 9 | 2025 | 7604 | 0.310 |
Why?
| | Testosterone | 3 | 2025 | 409 | 0.300 |
Why?
| | Running | 2 | 2023 | 230 | 0.300 |
Why?
| | Pulse Wave Analysis | 5 | 2022 | 272 | 0.290 |
Why?
| | Animals | 16 | 2025 | 36940 | 0.280 |
Why?
| | Diabetes Complications | 2 | 2021 | 227 | 0.280 |
Why?
| | Treatment Outcome | 11 | 2025 | 10811 | 0.270 |
Why?
| | Epidermal Growth Factor | 2 | 2024 | 177 | 0.270 |
Why?
| | Metabolic Syndrome | 3 | 2021 | 354 | 0.270 |
Why?
| | Canagliflozin | 3 | 2023 | 10 | 0.270 |
Why?
| | Heat Stress Disorders | 2 | 2018 | 76 | 0.250 |
Why?
| | Dipeptidyl-Peptidase IV Inhibitors | 3 | 2025 | 47 | 0.250 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 3 | 2021 | 82 | 0.250 |
Why?
| | Diabetes Mellitus | 3 | 2021 | 1040 | 0.240 |
Why?
| | Severity of Illness Index | 3 | 2021 | 2828 | 0.240 |
Why?
| | Age Factors | 7 | 2019 | 3295 | 0.240 |
Why?
| | Double-Blind Method | 4 | 2025 | 1993 | 0.240 |
Why?
| | Gliclazide | 1 | 2025 | 2 | 0.240 |
Why?
| | Linagliptin | 1 | 2025 | 5 | 0.240 |
Why?
| | Time Factors | 6 | 2018 | 6828 | 0.240 |
Why?
| | Hydrogen-Ion Concentration | 2 | 2018 | 560 | 0.240 |
Why?
| | Colorado | 4 | 2017 | 4565 | 0.240 |
Why?
| | Leucine | 2 | 2024 | 111 | 0.230 |
Why?
| | Fatty Acid Binding Protein 3 | 1 | 2024 | 6 | 0.230 |
Why?
| | Predictive Value of Tests | 4 | 2018 | 2031 | 0.230 |
Why?
| | Vascular Cell Adhesion Molecule-1 | 1 | 2024 | 39 | 0.230 |
Why?
| | Early Diagnosis | 2 | 2017 | 242 | 0.230 |
Why?
| | Citric Acid Cycle | 1 | 2024 | 57 | 0.230 |
Why?
| | Glucagon-Like Peptide 1 | 2 | 2025 | 135 | 0.230 |
Why?
| | Gray Matter | 1 | 2025 | 80 | 0.220 |
Why?
| | Renin | 2 | 2022 | 35 | 0.220 |
Why?
| | Androgen Antagonists | 1 | 2025 | 82 | 0.220 |
Why?
| | Estradiol | 2 | 2025 | 521 | 0.220 |
Why?
| | Diuretics | 2 | 2023 | 74 | 0.220 |
Why?
| | Lipoproteins | 2 | 2022 | 168 | 0.220 |
Why?
| | Endothelin Receptor Antagonists | 2 | 2024 | 62 | 0.220 |
Why?
| | Sex Factors | 4 | 2025 | 2071 | 0.220 |
Why?
| | Mineralocorticoid Receptor Antagonists | 2 | 2024 | 54 | 0.210 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2024 | 128 | 0.210 |
Why?
| | Receptors, Vasopressin | 2 | 2021 | 20 | 0.210 |
Why?
| | Inappropriate ADH Syndrome | 1 | 2023 | 8 | 0.210 |
Why?
| | Cysts | 1 | 2024 | 113 | 0.200 |
Why?
| | Magnetic Resonance Imaging | 3 | 2025 | 3566 | 0.200 |
Why?
| | Hyponatremia | 1 | 2023 | 42 | 0.200 |
Why?
| | Fluorocarbons | 1 | 2024 | 117 | 0.200 |
Why?
| | Longitudinal Studies | 5 | 2024 | 2844 | 0.200 |
Why?
| | Malates | 1 | 2022 | 7 | 0.190 |
Why?
| | Fumarates | 1 | 2022 | 9 | 0.190 |
Why?
| | Consensus | 2 | 2022 | 683 | 0.190 |
Why?
| | Threonine | 1 | 2022 | 47 | 0.190 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2023 | 125 | 0.190 |
Why?
| | Carboxylic Acids | 1 | 2022 | 34 | 0.190 |
Why?
| | Biopsy | 2 | 2025 | 1129 | 0.190 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2023 | 195 | 0.190 |
Why?
| | Phenylalanine | 1 | 2022 | 68 | 0.190 |
Why?
| | Amino Acids | 2 | 2024 | 497 | 0.190 |
Why?
| | Pathology, Clinical | 1 | 2022 | 36 | 0.190 |
Why?
| | Rats | 2 | 2024 | 5647 | 0.180 |
Why?
| | Chemokine CCL2 | 1 | 2022 | 115 | 0.180 |
Why?
| | Arizona | 1 | 2021 | 81 | 0.180 |
Why?
| | Glycine | 1 | 2022 | 176 | 0.180 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2025 | 752 | 0.170 |
Why?
| | Osmolar Concentration | 2 | 2018 | 171 | 0.170 |
Why?
| | p-Aminohippuric Acid | 1 | 2020 | 6 | 0.170 |
Why?
| | Oxidation-Reduction | 1 | 2024 | 1060 | 0.170 |
Why?
| | Tryptophan | 1 | 2022 | 183 | 0.170 |
Why?
| | Interleukin-18 | 1 | 2022 | 236 | 0.170 |
Why?
| | Multivariate Analysis | 2 | 2014 | 1509 | 0.170 |
Why?
| | Furosemide | 1 | 2020 | 37 | 0.170 |
Why?
| | Nephrosis | 1 | 2020 | 6 | 0.170 |
Why?
| | Natriuretic Peptide, Brain | 1 | 2021 | 99 | 0.170 |
Why?
| | Japan | 5 | 2017 | 115 | 0.170 |
Why?
| | Asymptomatic Diseases | 2 | 2019 | 89 | 0.170 |
Why?
| | Diabetic Neuropathies | 1 | 2021 | 94 | 0.170 |
Why?
| | Transgender Persons | 1 | 2023 | 186 | 0.160 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 2 | 2024 | 201 | 0.160 |
Why?
| | Calcium Channel Blockers | 1 | 2021 | 167 | 0.160 |
Why?
| | Sodium-Glucose Transporter 1 | 1 | 2019 | 11 | 0.160 |
Why?
| | Body Water | 1 | 2019 | 21 | 0.160 |
Why?
| | Diabetic Foot | 1 | 2019 | 24 | 0.160 |
Why?
| | Glycolysis | 1 | 2021 | 321 | 0.160 |
Why?
| | Models, Biological | 3 | 2016 | 1783 | 0.160 |
Why?
| | Glomerulonephritis | 1 | 2019 | 47 | 0.150 |
Why?
| | Glycosides | 1 | 2019 | 36 | 0.150 |
Why?
| | Blood Chemical Analysis | 1 | 2019 | 99 | 0.150 |
Why?
| | Postmenopause | 1 | 2021 | 366 | 0.150 |
Why?
| | Software | 2 | 2025 | 665 | 0.150 |
Why?
| | beta 2-Microglobulin | 1 | 2018 | 50 | 0.150 |
Why?
| | Proof of Concept Study | 3 | 2025 | 78 | 0.150 |
Why?
| | Myocardial Contraction | 1 | 2020 | 341 | 0.150 |
Why?
| | Endothelial Cells | 1 | 2024 | 785 | 0.150 |
Why?
| | Body Temperature Regulation | 1 | 2019 | 97 | 0.150 |
Why?
| | Microscopy, Polarization | 1 | 2018 | 31 | 0.150 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2018 | 90 | 0.150 |
Why?
| | Child, Preschool | 4 | 2025 | 11074 | 0.140 |
Why?
| | Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 42 | 0.140 |
Why?
| | Allopurinol | 1 | 2018 | 63 | 0.140 |
Why?
| | Pharmaceutical Preparations | 1 | 2020 | 179 | 0.140 |
Why?
| | Energy Metabolism | 1 | 2024 | 922 | 0.140 |
Why?
| | Mice | 5 | 2025 | 17787 | 0.140 |
Why?
| | Obesity, Metabolically Benign | 1 | 2017 | 4 | 0.140 |
Why?
| | Weight Loss | 2 | 2020 | 787 | 0.140 |
Why?
| | Prehypertension | 1 | 2017 | 28 | 0.140 |
Why?
| | Glucose Tolerance Test | 2 | 2019 | 366 | 0.140 |
Why?
| | Glomerulosclerosis, Focal Segmental | 1 | 2017 | 47 | 0.140 |
Why?
| | Deamino Arginine Vasopressin | 1 | 2016 | 12 | 0.130 |
Why?
| | Urinary Calculi | 1 | 2017 | 12 | 0.130 |
Why?
| | Life Style | 1 | 2019 | 490 | 0.130 |
Why?
| | Hyperthermia, Induced | 1 | 2018 | 116 | 0.130 |
Why?
| | Ventricular Dysfunction, Left | 1 | 2020 | 382 | 0.130 |
Why?
| | Peptide Fragments | 1 | 2021 | 706 | 0.130 |
Why?
| | Magnetic Resonance Angiography | 1 | 2018 | 240 | 0.130 |
Why?
| | Dehydration | 1 | 2016 | 51 | 0.130 |
Why?
| | Blood Banks | 1 | 2016 | 41 | 0.130 |
Why?
| | Precision Medicine | 1 | 2020 | 429 | 0.130 |
Why?
| | Morbidity | 1 | 2017 | 324 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 697 | 0.130 |
Why?
| | Regional Blood Flow | 1 | 2018 | 474 | 0.130 |
Why?
| | Cardiorespiratory Fitness | 1 | 2017 | 55 | 0.130 |
Why?
| | Tomography, X-Ray Computed | 2 | 2018 | 2691 | 0.130 |
Why?
| | Disease Models, Animal | 5 | 2021 | 4295 | 0.130 |
Why?
| | Vasodilation | 1 | 2020 | 499 | 0.130 |
Why?
| | Anti-Inflammatory Agents | 1 | 2020 | 496 | 0.130 |
Why?
| | Cognition | 1 | 2024 | 1153 | 0.120 |
Why?
| | Vitreoretinopathy, Proliferative | 1 | 2016 | 14 | 0.120 |
Why?
| | Survival Rate | 2 | 2017 | 1972 | 0.120 |
Why?
| | Logistic Models | 3 | 2017 | 2074 | 0.120 |
Why?
| | Linear Models | 2 | 2017 | 849 | 0.120 |
Why?
| | Heart Rate | 1 | 2019 | 822 | 0.120 |
Why?
| | Echocardiography, Doppler | 1 | 2016 | 108 | 0.120 |
Why?
| | Hot Temperature | 1 | 2018 | 391 | 0.120 |
Why?
| | Filtration | 1 | 2015 | 72 | 0.110 |
Why?
| | Liver Diseases | 1 | 2018 | 315 | 0.110 |
Why?
| | Risk Assessment | 4 | 2019 | 3457 | 0.110 |
Why?
| | Apolipoproteins | 1 | 2014 | 33 | 0.110 |
Why?
| | Enzyme Inhibitors | 1 | 2018 | 840 | 0.110 |
Why?
| | Blood Pressure Determination | 1 | 2015 | 157 | 0.110 |
Why?
| | Purines | 1 | 2015 | 176 | 0.110 |
Why?
| | Achievement | 1 | 2014 | 58 | 0.110 |
Why?
| | Phenotype | 1 | 2022 | 3196 | 0.110 |
Why?
| | Stress, Mechanical | 1 | 2016 | 485 | 0.110 |
Why?
| | Immunity, Innate | 1 | 2019 | 828 | 0.110 |
Why?
| | Primary Prevention | 1 | 2015 | 196 | 0.100 |
Why?
| | Liver | 2 | 2021 | 1943 | 0.100 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2019 | 1477 | 0.100 |
Why?
| | Exercise Test | 1 | 2016 | 625 | 0.100 |
Why?
| | Adenosine Triphosphate | 1 | 2015 | 491 | 0.100 |
Why?
| | Biomechanical Phenomena | 1 | 2016 | 810 | 0.100 |
Why?
| | Research Design | 1 | 2019 | 1139 | 0.100 |
Why?
| | Cholesterol | 1 | 2014 | 410 | 0.100 |
Why?
| | United States | 3 | 2024 | 14841 | 0.100 |
Why?
| | Antihypertensive Agents | 1 | 2016 | 494 | 0.090 |
Why?
| | Aged, 80 and over | 3 | 2018 | 7635 | 0.090 |
Why?
| | Retrospective Studies | 8 | 2025 | 15657 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2019 | 2833 | 0.090 |
Why?
| | Regression Analysis | 1 | 2014 | 1024 | 0.090 |
Why?
| | Feasibility Studies | 1 | 2015 | 956 | 0.090 |
Why?
| | Vascular Diseases | 1 | 2013 | 243 | 0.090 |
Why?
| | Exercise | 1 | 2022 | 2057 | 0.090 |
Why?
| | Ambulatory Care | 1 | 2015 | 546 | 0.090 |
Why?
| | Societies, Medical | 1 | 2015 | 820 | 0.080 |
Why?
| | Hematocrit | 2 | 2021 | 96 | 0.080 |
Why?
| | Gene Expression Regulation | 1 | 2019 | 2607 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1587 | 0.080 |
Why?
| | Fructokinases | 2 | 2021 | 32 | 0.080 |
Why?
| | Registries | 1 | 2016 | 2035 | 0.070 |
Why?
| | Inflammation | 2 | 2021 | 2837 | 0.070 |
Why?
| | Prevalence | 3 | 2019 | 2734 | 0.070 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3284 | 0.070 |
Why?
| | Fibrosis | 2 | 2021 | 552 | 0.060 |
Why?
| | Infant | 2 | 2025 | 9465 | 0.060 |
Why?
| | Postprandial Period | 1 | 2025 | 107 | 0.060 |
Why?
| | Pregnancy | 1 | 2017 | 6763 | 0.060 |
Why?
| | Isoleucine | 1 | 2024 | 15 | 0.050 |
Why?
| | Valine | 1 | 2024 | 82 | 0.050 |
Why?
| | Obesity, Abdominal | 1 | 2024 | 48 | 0.050 |
Why?
| | Mice, Inbred C57BL | 3 | 2021 | 5757 | 0.050 |
Why?
| | Aging | 1 | 2014 | 1864 | 0.050 |
Why?
| | Antibodies | 1 | 2025 | 410 | 0.050 |
Why?
| | Bromocriptine | 1 | 2022 | 30 | 0.050 |
Why?
| | Multicenter Studies as Topic | 1 | 2024 | 310 | 0.050 |
Why?
| | RNA, Transfer | 1 | 2024 | 138 | 0.050 |
Why?
| | Infant, Newborn | 1 | 2014 | 6079 | 0.050 |
Why?
| | Benzbromarone | 1 | 2022 | 1 | 0.050 |
Why?
| | Environmental Pollutants | 1 | 2024 | 159 | 0.050 |
Why?
| | Aldosterone | 1 | 2022 | 45 | 0.050 |
Why?
| | Cytokines | 2 | 2021 | 2085 | 0.050 |
Why?
| | Glycoproteins | 1 | 2024 | 342 | 0.050 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2021 | 30 | 0.050 |
Why?
| | Adenine | 1 | 2023 | 271 | 0.050 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2021 | 106 | 0.050 |
Why?
| | Inulin | 1 | 2021 | 7 | 0.040 |
Why?
| | Hep G2 Cells | 1 | 2021 | 67 | 0.040 |
Why?
| | Drinking | 1 | 2021 | 42 | 0.040 |
Why?
| | Serum Albumin | 1 | 2021 | 150 | 0.040 |
Why?
| | Uricosuric Agents | 1 | 2020 | 2 | 0.040 |
Why?
| | Diuretics, Osmotic | 1 | 2020 | 2 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2023 | 412 | 0.040 |
Why?
| | Mendelian Randomization Analysis | 1 | 2020 | 50 | 0.040 |
Why?
| | Cell Hypoxia | 1 | 2021 | 226 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2022 | 564 | 0.040 |
Why?
| | Diastole | 1 | 2020 | 149 | 0.040 |
Why?
| | Chemokines | 1 | 2021 | 228 | 0.040 |
Why?
| | Systole | 1 | 2020 | 189 | 0.040 |
Why?
| | Cytoprotection | 1 | 2019 | 56 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2024 | 579 | 0.040 |
Why?
| | Netherlands | 1 | 2019 | 88 | 0.040 |
Why?
| | Neuropsychological Tests | 1 | 2024 | 1023 | 0.040 |
Why?
| | Drug Interactions | 1 | 2021 | 410 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1215 | 0.040 |
Why?
| | Preoperative Period | 1 | 2019 | 129 | 0.040 |
Why?
| | Magnetic Resonance Imaging, Cine | 1 | 2020 | 193 | 0.040 |
Why?
| | Critical Illness | 1 | 2025 | 811 | 0.040 |
Why?
| | Cognitive Dysfunction | 1 | 2024 | 383 | 0.040 |
Why?
| | Incretins | 1 | 2018 | 22 | 0.040 |
Why?
| | Macular Edema | 1 | 2018 | 43 | 0.040 |
Why?
| | Photography | 1 | 2018 | 96 | 0.040 |
Why?
| | Renal Elimination | 1 | 2018 | 6 | 0.040 |
Why?
| | Inflammation Mediators | 1 | 2021 | 513 | 0.040 |
Why?
| | Xanthine Oxidase | 1 | 2018 | 81 | 0.040 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2018 | 73 | 0.030 |
Why?
| | Diet Therapy | 1 | 2018 | 37 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2021 | 435 | 0.030 |
Why?
| | Cardiovascular System | 1 | 2019 | 137 | 0.030 |
Why?
| | Anti-Obesity Agents | 1 | 2018 | 57 | 0.030 |
Why?
| | Lipoproteins, LDL | 1 | 2017 | 116 | 0.030 |
Why?
| | Renal Plasma Flow, Effective | 1 | 2016 | 1 | 0.030 |
Why?
| | Blood Urea Nitrogen | 1 | 2016 | 54 | 0.030 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2017 | 85 | 0.030 |
Why?
| | Thiazolidinediones | 1 | 2018 | 137 | 0.030 |
Why?
| | Tomography, Optical Coherence | 1 | 2018 | 213 | 0.030 |
Why?
| | Aldehyde Reductase | 1 | 2016 | 29 | 0.030 |
Why?
| | Water-Electrolyte Balance | 1 | 2016 | 34 | 0.030 |
Why?
| | Infusions, Intravenous | 1 | 2018 | 413 | 0.030 |
Why?
| | Ammonia | 1 | 2016 | 62 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2021 | 778 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2019 | 1266 | 0.030 |
Why?
| | Age Distribution | 1 | 2017 | 392 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 375 | 0.030 |
Why?
| | Collagen | 1 | 2018 | 452 | 0.030 |
Why?
| | Waist Circumference | 1 | 2015 | 143 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2018 | 1236 | 0.030 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2019 | 641 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 3015 | 0.030 |
Why?
| | Circadian Rhythm | 1 | 2017 | 468 | 0.030 |
Why?
| | Complement Activation | 1 | 2016 | 415 | 0.030 |
Why?
| | Exercise Therapy | 1 | 2018 | 443 | 0.030 |
Why?
| | Heart Ventricles | 1 | 2018 | 788 | 0.020 |
Why?
| | Gene-Environment Interaction | 1 | 2014 | 192 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1622 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2486 | 0.020 |
Why?
| | Peptides | 1 | 2018 | 985 | 0.020 |
Why?
| | Models, Statistical | 1 | 2015 | 669 | 0.020 |
Why?
| | Databases, Factual | 1 | 2017 | 1357 | 0.020 |
Why?
| | Non-alcoholic Fatty Liver Disease | 1 | 2014 | 279 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1704 | 0.020 |
Why?
| | Hospitalization | 1 | 2017 | 2199 | 0.020 |
Why?
| | Neoplasms | 1 | 2014 | 2671 | 0.010 |
Why?
|
|
Bjornstad's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|